Showing results (91-100 of 133) with videos related to

Sort By:
Pageof 14
The Journal of Allergy and Clinical Immunology|May 14, 2022
Distinct disease-specific Tfh cell populations in 2 different fibrotic diseases: IgG4-related disease and Kimura diseaseRyusuke Munemura, Takashi Maehara, Yuka Murakami, et al.
Scientific Reports|September 14, 2022
Cytotoxic CD8+ T cells may be drivers of tissue destruction in Sjögren's syndromeNaoki Kaneko, Hu Chen, Cory A Perugino, et al.
Life Science Alliance|July 10, 2018
The expansion in lymphoid organs of IL-4+ BATF+ T follicular helper cells is linked to IgG4 class switching in vivoTakashi Maehara, Hamid Mattoo, Vinay S Mahajan, et al.
The Lancet. Rheumatology|June 2, 2024
Sex as a predictor of clinical phenotype and determinant of immune response in IgG4-related disease: a retrospective study of patients fulfilling the American College of Rheumatology-European League Against Rheumatism classification criteriaIsha Jha, Grace A McMahon, Cory A Perugino, et al.
The Journal of Allergy and Clinical Immunology|March 15, 2016
Clonal expansion of CD4(+) cytotoxic T lymphocytes in patients with IgG4-related diseaseHamid Mattoo, Vinay S Mahajan, Takashi Maehara, et al.
Nature Medicine|November 9, 2019
Preventing dysbiosis of the neonatal mouse intestinal microbiome protects against late-onset sepsisJeffrey R Singer, Emily G Blosser, Carlene L Zindl, et al.
The Journal of Allergy and Clinical Immunology|December 13, 2023
Granzyme K- and amphiregulin-expressing cytotoxic T cells and activated extrafollicular B cells are potential drivers of IgG4-related diseaseRisako Koga, Takashi Maehara, Ryuichi Aoyagi, et al.
Nature Immunology|September 13, 2005
Activation of bone marrow-resident memory T cells by circulating, antigen-bearing dendritic cellsLois L Cavanagh, Roberto Bonasio, Irina B Mazo, et al.
The Journal of Clinical Investigation|January 29, 2020
Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosisTakashi Maehara, Naoki Kaneko, Cory A Perugino, et al.
The Lancet. Rheumatology|January 22, 2024
Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trialCory A Perugino, Zachary S Wallace, Debra J Zack, et al.
Pageof 14